You are here

Pfizer beats Sanofi to buy Medivation for US$14b

It gains cancer drug Xtandi with acquisition; analysts project it to generate US$1.33b in annual sales by 2020

New York

PFIZER Inc has agreed to buy Medivation Inc for about US$14 billion, gaining a blockbuster prostate cancer treatment and leaving French drugmaker Sanofi jilted.

Pfizer will pay US$81.50 a share in cash, the companies said in a statement on Monday. Shares of Medivation,